Holen Sie sich die Stockscreener-App
9.07
1.31%
-0.12
Handel nachbörslich:
9.25
0.18
+1.98%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.19
Offen:
$9.18
24-Stunden-Volumen:
1.03M
Relative Volume:
0.71
Marktkapitalisierung:
$1.23B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-17.11
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+0.00%
1M Leistung:
+12.67%
6M Leistung:
+13.38%
1J Leistung:
+63.13%
1-Tages-Spanne:
$9.035
$9.36
1-Wochen-Bereich:
$8.55
$9.36
52-Wochen-Spanne:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
9.07 | 1.20B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
What analysts say about Aurinia Pharmaceuticals Inc. stockDynamic profit expansion - Autocar Professional
Is Aurinia Pharmaceuticals Inc. a good long term investmentUnmatched profit potential - Autocar Professional
What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser
How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser
How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest
Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com
Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq
Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail
Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News
(AUPH) Trading Report - news.stocktradersdaily.com
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance
Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 04 '25 |
Sale |
7.92 |
57,607 |
456,247 |
509,276 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 03 '25 |
Sale |
8.00 |
65,902 |
527,216 |
739,456 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 04 '25 |
Sale |
7.92 |
58,991 |
467,209 |
680,465 |
| TANG KEVIN | Director |
Mar 04 '25 |
Buy |
7.96 |
748,038 |
5,953,304 |
10,029,500 |
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):